This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics.
This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "e;second generation"e; drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
Our site uses cookies and similar technologies to offer you a better experience. We use analytical cookies (our own and third party) to understand and improve your browsing experience, and advertising cookies (our own and third party) to send you advertisements in line with your preferences. To modify or opt-out of the use of some or all of our cookies, please go to “Manage Cookies” or view our Cookie Policy to find out more. By clicking “Accept all” you consent to the use of these cookies.
